Scientific Research and Essays

  • Abbreviation: Sci. Res. Essays
  • Language: English
  • ISSN: 1992-2248
  • DOI: 10.5897/SRE
  • Start Year: 2006
  • Published Articles: 2753

Review

Nanomedicines: Challenges and perspectives for future nanotechnology in the healthcare system

Ajazuddin
  • Ajazuddin
  • Rungta College of Pharmaceutical Sciences and Research, Kohka-Kurud Road, Bhilai, Chhattisgarh, India, 490 024.
  • Google Scholar
Sabahuddin Siddique
  • Sabahuddin Siddique
  • Patel College of Pharmacy, Madhyanchal Professional University, Bhopal, Madhya Pradesh, India.
  • Google Scholar
Amit Alexander
  • Amit Alexander
  • Rungta College of Pharmaceutical Sciences and Research, Kohka-Kurud Road, Bhilai, Chhattisgarh, India, 490 024.
  • Google Scholar
Pooja Yadav
  • Pooja Yadav
  • Rungta College of Pharmaceutical Sciences and Research, Kohka-Kurud Road, Bhilai, Chhattisgarh, India, 490 024.
  • Google Scholar
Mukta Agrawal
  • Mukta Agrawal
  • Rungta College of Pharmaceutical Sciences and Research, Kohka-Kurud Road, Bhilai, Chhattisgarh, India, 490 024.
  • Google Scholar
Ahmed M Shehata
  • Ahmed M Shehata
  • Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
  • Google Scholar
Mahmoud A Shaker
  • Mahmoud A Shaker
  • Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia
  • Google Scholar
Syed Ata Ur Rahman
  • Syed Ata Ur Rahman
  • Pharmaceutics and Pharmaceutical Technology Department, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
  • Google Scholar
Mohi Iqbal M Abdul
  • Mohi Iqbal M Abdul
  • Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
  • Google Scholar
Mohamed A. Shaker
  • Mohamed A. Shaker
  • Pharmaceutics Department, Faculty of Pharmacy, Helwan University, P. O. Box 11795, Cairo, Egypt.
  • Google Scholar


  •  Received: 01 February 2019
  •  Accepted: 29 March 2019
  •  Published: 15 April 2019

References

Abeer S (2012). Future medicine: Nanomedicine. JIMSA 25(3):187-192.

 

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A (2018a). Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-alzheimer drugs. Journal of Controlled Release 281:139-177.
Crossref

 

Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Hamano N, Li SD, Chougule M, Shoyele SA, Gupta U, Ajazuddin, Alexander A (2018b). Recent advancements in the field of nanotechnology for the delivery of anti-alzheimer drug in the brain region. Expert opinion on drug delivery 15(6):589-617.
Crossref

 

Ahamed M (2011). Toxic response of nickel nanoparticles in human lung epithelial a549 cells. Toxicology in Vitro 25(4):930-936.
Crossref

 

Akhter S, Ahmad I, Ahmad MZ, Ramazani F, Singh A, Rahman Z, Ahmad FJ, Storm G, Kok RJ (2013). Nanomedicines as cancer therapeutics: Current status. Current Cancer Drug Targets 13(4):362-378.
Crossref

 

Alexander A, Saraf S, Agrawal M, Patel R, Agrawal P, Khan J (2018). Amalgamation of stem cells with nanotechnology: A unique therapeutic approach. Current Stem Cell Research and Therapy.
Crossref

 

Antimisiaris SG, Mourtas S, Markoutsa E, Skouras A, Papadia K (2014). Nanoparticles for diagnosis and/or treatment of alzheimer's disease. In: Advanced healthcare materials. John Wiley & Sons, Inc., pp. 87-179.
Crossref

 

Arora P, Sindhu A, Dilbaghi N, Chaudhury A, Rajakumar G, Rahuman AA (2012). Nano-regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans. Journal of Cellular and Molecular Medicine 16(9):1991-2000.
Crossref

 

Aschengrau ASG (2008). Essentials of epidemiology in public health. MA: Jones and Bartlett Publishers.

 

Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016). Nanoparticle-based medicines: A review of fda-approved materials and clinical trials to date. Pharmaceutical Research 33(10):2373-2387.
Crossref

 

Bouck N, Stellmach V, Hsu SC (1996). How tumors become angiogenic. Advances in Cancer Research 69:135-174.
Crossref

 

Brand W, Noorlander CW, Giannakou C, De Jong WH, MW Kooi, MV Park, RJ Vandebriel, IE Bosselaers, JH Scholl, RE Geertsma (2017). Nanomedicinal products: A survey on specific toxicity and side effects. International Journal of Nanomedicine, 12:6107-6129.
Crossref

 

Cerrillo C, Barandika G, Igartua A, Areitioaurtena O, Mendoza G (2017). Key challenges for nanotechnology: Standardization of ecotoxicity testing. Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis and Ecotoxicology Reviews 35(2):104-126.
Crossref

 

Chen D, Love KT, Chen Y, Eltoukhy AA, Kastrup C, Sahay G, Jeon A, Dong Y, Whitehead KA, Anderson DG (2012). Rapid discovery of potent sirna-containing lipid nanoparticles enabled by controlled microfluidic formulation. Journal of the American Chemical Society 134(16):6948-6951.
Crossref

 

Ciappellano SG, Tedesco E, Venturini M, Benetti F (2016). In vitro toxicity assessment of oral nanocarriers. Advanced drug delivery reviews 106(Pt B):381-401.
Crossref

 

Costa C, Brandao F, Bessa MJ, Costa S, Valdiglesias V, Kilic G, Fernandez-Bertolez N, Quaresma P, Pereira E, Pasaro E, Laffon B, Teixeira JP (2016). In vitro cytotoxicity of superparamagnetic iron oxide nanoparticles on neuronal and glial cells. Evaluation of nanoparticle interference with viability tests. Journal of Applied Toxicology 36(3):361-372.
Crossref

 

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008). The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 7(1):11-20.
Crossref

 

Devatha CP, Jagadeesh K, Patil M (2018). Effect of green synthesized iron nanoparticles by azardirachta indica in different proportions on antibacterial activity. Environmental Nanotechnology, Monitoring and Management 9:85-94.
Crossref

 

Dhawan A, Sharma V (2010). Toxicity assessment of nanomaterials: Methods and challenges. Analytical and Bioanalytical Chemistry 398(2):589-605.
Crossref

 

Dobrovolskaia MA, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE (2010). Ambiguities in applying traditional limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine (London, England) 5(4):555-562.
Crossref

 

Dvir T, Timko BP, Brigham MD, Naik SR, Karajanagi SS, Levy O, Jin H, Parker KK, Langer R, Kohane DS (2011). Nanowired three-dimensional cardiac patches. Nature Nanotechnology 6(11):720-725.
Crossref

 

Escamilla-Rivera V, Uribe-Ramirez M, Gonzalez-Pozos S, Lozano O, Lucas S, De Vizcaya-Ruiz A (2016). Protein corona acts as a protective shield against fe3o4-peg inflammation and ros-induced toxicity in human macrophages. Toxicology Letters 240(1):172-184.
Crossref

 

Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013). The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine 9(1):1-14.
Crossref

 

Fabian E, Landsiedel R, Ma-Hock L, Wiench K, Wohlleben W, van Ravenzwaay B (2008). Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Archives of toxicology 82(3):151-157.
Crossref

 

Feng L, XR Qi, XJ Zhou, Y Maitani, Wang SC, Jiang Y, Nagai T (2006).

 

Pharmaceutical and immunological evaluation of a single-dose hepatitis b vaccine using plga microspheres. Journal of controlled release: Official Journal of the Controlled Release Society 112(1):35-42.
Crossref

 

Han Y-g, Xu J, Li Z-g, Ren G-g, Z Yang (2012). In vitro toxicity of multi-walled carbon nanotubes in c6 rat glioma cells. NeuroToxicology 33(5):1128-1134.
Crossref

 

Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M (2016). Nanomedicines: From bench to bedside and beyond. The AAPS Journal 18(6):1373-1378.
Crossref

 

Hu Y, Fine DH, Tasciotti E, Bouamrani A, Ferrari M (2011). Nanodevices in diagnostics. Wiley interdisciplinary reviews. Nanomedicine and Nanobiotechnology 3(1):11-32.
Crossref

 

Iqbal J, Abbasi BA, Ahmad R, Mahmood T, Ali B, Khalil AT, Kanwal S, Shah SA, Alam MM, Badshah H, Munir A (2018). Nanomedicines for developing cancer nanotherapeutics: From benchtop to bedside and beyond. Applied Microbiology and Biotechnology 102(22):9449-9470.
Crossref

 

Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, Langer R, Farokhzad OC (2008). Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano letters 8(9):2906-2912.
Crossref

 

Kaur IP, Kakkar V, Deol PK, Yadav M, Singh M Sharma I (2014). Issues and concerns in nanotech product development and its commercialization. Journal of controlled release Official Journal of the Controlled Release Society 193:51-62.
Crossref

 

Khan MI, Mohammad A, Patil G, Naqvi SA, Chauhan LK, Ahmad I (2012). Induction of ros, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles. Biomaterials 33(5):1477-1488.
Crossref

 

Khare S, Alexander A, Amit N (2014). Biomedical applications of nanobiotechnology for drug design, delivery and diagnostics. Research Journal of Pharmacy and Technology 7(8):8.

 

Khorasani AA, Weaver JL, Salvador-Morales C (2014). Closing the gap: Accelerating the translational process in nanomedicine by proposing standardized characterization techniques. International Journal of Nanomedicine 9:5729-5751.
Crossref

 

Kim Y, Lee CB, Ma M, Mulder WJ, Fayad ZA, Farokhzad OC, Langer R (2012). Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices. Nano letters, 12(7): 3587-3591. DOI 10.1021/nl301253v.
https://doi.org/10.1021/nl301253v

 

Kroll, A., M.H. Pillukat, D. Hahn, J. Schnekenburger (2009). Current in vitro methods in nanoparticle risk assessment: Limitations and challenges. European Journal of Pharmaceutics and Biopharmaceutics, 72(2): 370-377. 
Crossref

 

Kroll, A., M.H. Pillukat, D. Hahn, J. Schnekenburger (2012). Interference of engineered nanoparticles with in vitro toxicity assays. Archives of toxicology, 86(7): 1123-1136. DOI 10.1007/s00204-012-0837-z.
Crossref

 

Kumar H, Gothwal A, Khan I, Nakhate KT, Alexander A, Singh V, Gupta U (2017). Galactose-anchored gelatin nanoparticles for primaquine delivery and improved pharmacokinetics: A biodegradable and safe approach for effective antiplasmodial activity against p. Falciparum 3d7 and in vivo hepatocyte targeting. Molecular pharmaceutics, 14(10):3356-3369.
Crossref

 

Linkov I, Satterstrom FK, Corey LM (2008). Nanotoxicology and nanomedicine: Making hard decisions. Nanomedicine: Nanotechnology, Biology and Medicine 4(2):167-171.
Crossref

 

Liu H, Ma L, Zhao J, Liu J, Yan J, Ruan J, Hong F (2009). Biochemical toxicity of nano-anatase tio2 particles in mice. Biological trace element research 129(1-3):170-180.
Crossref

 

Lozano O, Laloy J, Alpan L, Mejia J, Rolin S, Toussaint O, Dogne JM, Lucas S, Masereel B (2012a). Effects of sic nanoparticles orally administered in a rat model: Biodistribution, toxicity and elemental composition changes in feces and organs. Toxicology and Applied Pharmacology 264(2):232-245.
Crossref

 

Lozano O, Mejia J, Masereel B, Toussaint O, Lison D, Lucas S (2012b). Development of a pixe analysis method for the determination of the biopersistence of sic and tic nanoparticles in rat lungs. Nanotoxicology 6(3):263-271.
Crossref

 

Lv H, Zhang S, Wang B, Cui S, Yan J (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. Journal of Controlled Release: Official Journal of the Controlled Release Society 114(1):100-109.
Crossref

 

Maniam G, Mai CW, Zulkefeli M, Dufes C, Tan DM, Fu JY (2018). Challenges and opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Frontiers in Pharmacology 9:1358.
Crossref

 

Maynard AD, Warheit DB, Philbert MA (2011). The new toxicology of sophisticated materials: Nanotoxicology and beyond. Toxicological Sciences 120(Suppl 1):S109-129.
Crossref

 

Mulhopt S, Diabate S (2018). Characterization of nanoparticle batch-to-batch variability. Nanomaterials 8(5):311.
Crossref

 

Oberdorster G (2010). Safety assessment for nanotechnology and nanomedicine: Concepts of nanotoxicology. Journal of Internal Medicine 267(1):89-105.
Crossref

 

Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, Warheit D, Yang H (2005). Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Particle and Fibre Toxicology 2:8.
Crossref

 

Oostingh GJ, Casals E, Italiani P, Colognato R, Stritzinger R, Ponti J, Pfaller T, Kohl Y, Ooms D, Favilli F, Leppens H, Lucchesi D, Rossi F, Nelissen I, Thielecke H, Puntes VF, Duschl A, Boraschi D (2011). Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Particle and Fibre Toxicology 8(1):8.
Crossref

 

Park EJ, Lee GH, Shim HW, Kim JH, Cho MH, Kim DW (2014). Comparison of toxicity of different nanorod-type tio2 polymorphs in vivo and in vitro. Journal of applied toxicology. Journal of AT 34(4):357-366.
Crossref

 

Pautler M, Brenner S (2010). Nanomedicine: Promises and challenges for the future of public health. International Journal of Nanomedicine 5:803-809.
Crossref

 

Powell JJ, Faria N, Thomas-McKay E, Pele LC (2010). Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. Journal of Autoimmunity 34(3):J226-233.
Crossref

 

Pradhan M, Alexander A, Singh MR, Singh D, Saraf S, Saraf S (2018). Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomedicine and Pharmacotherapy 107:447-463.
Crossref

 

Resnik DB, Tinkle SS (2007). Ethical issues in clinical trials involving nanomedicine. Contemporary Clinical Trials 28(4):433-441.
Crossref

 

Rhee M, Valencia PM, Rodriguez MI, Langer R, Farokhzad OC, Karnik R (2011). Synthesis of size-tunable polymeric nanoparticles enabled by 3d hydrodynamic flow focusing in single-layer microchannels. Advanced materials (Deerfield Beach, Fla.). 23(12):H79-83.
Crossref

 

Saraf S, Gupta A, Alexander A, Khan J, Jangde M, Saraf S (2015). Advancements and avenues in nanophytomedicines for better pharmacological responses. Journal of Nanoscience and Nanotechnology 15(6):4070-4079.
Crossref

 

Shi J, Kantoff PW, Wooster R, Farokhzad OC (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature reviews. Cancer 17(1):20-37.
Crossref

 

Spagnou S, Miller AD, Keller M (2004). Lipidic carriers of sirna: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43(42):13348-13356.
Crossref

 

Tran S, DeGiovanni PJ, Piel B, Rai P (2017). Cancer nanomedicine: A review of recent success in drug delivery. Clinical and Translational Medicine 6(1):44.
Crossref

 

Ventola CL (2012). The nanomedicine revolution: Part 1: Emerging concepts. Pharmacy and Therapeutics 37(9):512-525.

 

Verma C, Janghel A, Deo S, Raut P, Bhosle D, Kumar SS, Agrawal M, Amit N, Sharma M, Giri T (2015). A comprehensive advancement on nanomedicines along with its various biomedical applications. Research Journal of Pharmacy and Technology 8(7):945-957.
Crossref

 

Wei A, Mehtala JG, Patri AK (2012). Challenges and opportunities in the advancement of nanomedicines. Journal of Controlled Release 164(2):236-246.
Crossref

 

Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H, Ferrari M, Zhao Y (2015). Safety of nanoparticles in medicine. Current Drug Targets 16(14):1671-1681.
Crossref

 

Xu J, Xu P, Li Z, Huang J, Yang Z (2012). Oxidative stress and apoptosis induced by hydroxyapatite nanoparticles in c6 cells. Journal of Biomedical Materials Research Part A 100(3):738-745.
Crossref

 

Zhang X, Li W, Yang Z (2015). Toxicology of nanosized titanium dioxide: An update. Archives of Toxicology 89(12):2207-2217.
Crossref